The mixed earnings report from Revance Therapeutics, with an EPS beat but a miss on sales forecasts, presents a neutral short-term impact on its stock price. The EPS beat is positive, indicating better cost management or higher profitability than expected. However, missing sales estimates could raise concerns about growth prospects or market demand. The year-over-year sales growth is a positive sign, but the miss on expectations may temper investor enthusiasm. Therefore, the overall impact is neutral as the positive and negative aspects of the report may balance each other out in the short term.